$351 Million is the total value of venBio Partners LLC's 9 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ALXO | ALX ONCOLOGY HLDGS INC | $78,472,000 | -52.1% | 9,699,925 | 0.0% | 22.34% | -38.5% | |
VENTYX BIOSCIENCES INC | $61,291,000 | -9.9% | 5,011,536 | 0.0% | 17.45% | +15.8% | ||
IMPL | IMPEL PHARMACEUTICALS INC | $25,721,000 | +46.3% | 2,759,791 | 0.0% | 7.32% | +87.9% | |
AKRO | AKERO THERAPEUTICS INC | $20,522,000 | -33.4% | 2,171,664 | 0.0% | 5.84% | -14.5% | |
VRNA | VERONA PHARMA PLCsponsored ads | $678,000 | -16.1% | 161,897 | 0.0% | 0.19% | +7.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VERONA PHARMA PLC | 15 | Q2 2022 | 22.2% |
AKERO THERAPEUTICS INC | 14 | Q3 2022 | 65.3% |
ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 73.8% |
HARMONY BIOSCIENCES HLDGS IN | 13 | Q3 2023 | 21.1% |
APELLIS PHARMACEUTICALS INC | 11 | Q2 2021 | 62.0% |
PHARVARIS N V | 11 | Q3 2023 | 25.2% |
IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.3% |
ELEVATION ONCOLOGY INC | 10 | Q3 2023 | 4.2% |
VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 42.7% |
PRECISION BIOSCIENCES INC | 7 | Q3 2020 | 62.0% |
View venBio Partners LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
View venBio Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.